ABSTRACT
High X-ray absorption combined with photothermal properties make bismuth nanoparticles (Bi NP) a promising agent for multimodal cancer theranostics. However, the synthesis of Bi NP by the "classical" chemical methods has numerous limitations, including potential toxicity of the produced nanomaterials. Here we studied in vitro toxicity of laser-synthesized Bi NP coated with Pluronic F-127 on mouse fibroblast cell line L929. The survival of L929 cells decreased linearly with increasing the concentration of Bi NP in a concentration range of 3-500 µg/ml; the LC50 value was 57 µg/ml. The unique combination of functional properties and moderate toxicity of the laser-synthesized Bi NP makes them a new promising platform for sensitization of multimodal cancer theranostics.
Subject(s)
Metal Nanoparticles , Animals , Mice , Bismuth/toxicity , Bismuth/chemistry , Cell Line, Tumor , Metal Nanoparticles/toxicity , Metal Nanoparticles/chemistry , Nanoparticles/toxicity , Nanoparticles/chemistry , Nanostructures , Neoplasms/metabolism , Phototherapy/methodsABSTRACT
The particular characteristics of hypoxia, immune suppression in the tumor microenvironment, and the lack of accurate imaging guidance lead to the limited effects of stereotactic body radiotherapy (SBRT) in reducing the recurrence rate and mortality of hepatocellular carcinoma (HCC). This research developed a novel theranostic agent based on Bi/Se nanoparticles (NPs), synthesized by a simple reduction reaction method for in vivo CT image-guided SBRT sensitization in mice. After loading Lenvatinib (Len), the obtained Bi/Se-Len NPs had excellent performance in reversing hypoxia and the immune suppression status of HCC. In vivo CT imaging results uncovered that the radiotherapy (RT) area could be accurately labeled after the injection of Bi/Se-Len NPs. Under Len's unique and robust properties, in vivo treatment was then carried out upon injection of Bi/Se-Len NPs, achieving excellent RT sensitization effects in a mouse HCC model. Comprehensive tests and histological stains revealed that Bi/Se-Len NPs could reshape and normalize tumor blood vessels, reduce the hypoxic situation of the tumor, and upregulate tumor-infiltrating CD4+ and CD8+ T lymphocytes around the tumors. Our work highlights an excellent proposal of Bi/Se-Len NPs as theranostic nanoparticles for image-guided HCC radiotherapy.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Contrast Media/therapeutic use , Liver Neoplasms/drug therapy , Metal Nanoparticles/therapeutic use , Tumor Microenvironment/drug effects , Animals , Bismuth/chemistry , Bismuth/therapeutic use , Bismuth/toxicity , Blood Vessels/drug effects , Carcinoma, Hepatocellular/diagnostic imaging , Cell Line, Tumor , Contrast Media/chemical synthesis , Contrast Media/toxicity , Drug Carriers/chemical synthesis , Drug Carriers/therapeutic use , Drug Carriers/toxicity , Female , Humans , Hypoxia/drug therapy , Liver Neoplasms/diagnostic imaging , Lymphocytes/drug effects , Metal Nanoparticles/chemistry , Metal Nanoparticles/toxicity , Mice, Inbred BALB C , Phenylurea Compounds/therapeutic use , Precision Medicine , Quantum Dots/chemistry , Quantum Dots/therapeutic use , Quantum Dots/toxicity , Quinolines/therapeutic use , Radiation-Sensitizing Agents/chemical synthesis , Radiation-Sensitizing Agents/therapeutic use , Radiation-Sensitizing Agents/toxicity , Radiosurgery , Selenium/chemistry , Selenium/therapeutic use , Selenium/toxicity , Tomography, X-Ray ComputedABSTRACT
BACKGROUNDS: Due to the unexpected side effects of the iodinated contrast agents, novel contrast agents for X-ray computed tomography (CT) imaging are urgently needed. Nanoparticles made by heavy metal elements are often employed, such as gold and bismuth. These nanoparticles have the advantages of long in vivo circulation time and tumor targeted ability. However, due to the long residence time in vivo, these nanoparticles may bring unexpected toxicity and, the preparation methods of these nanoparticles are complicated and time-consuming. METHODS: In this investigation, a small molecular bismuth chelate using diethylenetriaminepentaacetic acid (DPTA) as the chelating agent was proposed to be an ideal CT contrast agent. RESULTS: The preparation method is easy and cost-effective. Moreover, the bismuth agent show better CT imaging for kidney than iohexol in the aspect of improved CT values. Up to 500 µM, the bismuth agent show negligible toxicity to L02 cells and negligible hemolysis. And, the bismuth agent did not induce detectable morphology changes to the main organs of the mice after intravenously repeated administration at a high dose of 250 mg/kg. The pharmacokinetics of the bismuth agent follows the first-order elimination kinetics and, it has a short half-life time of 0.602 h. The rapid clearance from the body promised its excellent biocompatibility. CONCLUSIONS: This bismuth agent may serve as a potential candidate for developing novel contrast agent for CT imaging in clinical applications.
Subject(s)
Bismuth , Contrast Media , Tomography, X-Ray Computed/methods , Animals , Bismuth/chemistry , Bismuth/pharmacokinetics , Bismuth/toxicity , Contrast Media/chemistry , Contrast Media/pharmacokinetics , Contrast Media/toxicity , Iohexol/chemistry , Iohexol/pharmacokinetics , Kidney/diagnostic imaging , Kidney/metabolism , Metal Nanoparticles/chemistry , Metal Nanoparticles/toxicity , Mice , Pentetic Acid/chemistry , Pentetic Acid/pharmacokinetics , Tissue Distribution , Whole Body ImagingABSTRACT
Baby foods, from the Spanish market and prepared from meat, fish, vegetables, cereals, legumes, and fruits, were analyzed to obtain the concentration of antimony (Sb), arsenic (As), bismuth (Bi), and tellurium (Te) as toxic elements and selenium (Se) as essential element. An analytical procedure was employed based on atomic fluorescence spectroscopy which allowed to obtain accurate data at low levels of concentration. Values of 14 commercial samples, expressed in nanograms per gram fresh weight, ranged for Sb 0.66-6.9, As 4.5-242, Te 1.35-2.94, Bi 2.18-4.79, and Se 5.4-109. Additionally, speciation studies were performed based on data from a non-chromatographic screening method. It was concluded that tellurium and bismuth were mainly present as inorganic forms and selenium as organic form, and antimony and arsenic species depend on the ingredients of each baby food. Risk assessment considerations were made by comparing dietary intake of the aforementioned elements through the consumption of one baby food portion a day and recommended or tolerable guideline values.
Subject(s)
Antimony/analysis , Arsenic/analysis , Bismuth/analysis , Food Contamination , Infant Food/analysis , Selenium/analysis , Tellurium/analysis , Animals , Antimony/chemistry , Antimony/toxicity , Arsenic/chemistry , Arsenic/toxicity , Arsenicals/adverse effects , Arsenicals/analysis , Arsenicals/chemistry , Bismuth/chemistry , Bismuth/toxicity , Dietary Exposure , Environmental Pollutants/analysis , Environmental Pollutants/chemistry , Environmental Pollutants/toxicity , Fishes , Humans , Infant , Infant Food/adverse effects , Infant Food/economics , Infant Food/standards , Molecular Structure , No-Observed-Adverse-Effect Level , Nutritive Value , Organometallic Compounds/analysis , Organometallic Compounds/chemistry , Organometallic Compounds/toxicity , Organoselenium Compounds/analysis , Organoselenium Compounds/chemistry , Risk Assessment , Seafood/adverse effects , Seafood/analysis , Seafood/economics , Seafood/standards , Selenium/chemistry , Selenium/poisoning , Spain , Tellurium/chemistry , Tellurium/toxicityABSTRACT
In the early 16th century Gregorius Agricola reported on Bergsucht (miner's consumption) in mine workers in the Erzgebirge. About 350 years later, Härting and Hesse reported on large numbers of lung cancers among the mine-workers in the same mine district, thus confirming that Bergsucht primarily was lung cancer, but could also have been pnumoconiosis or tuberculosis or a combination of both. Mining for bismuth continued another 75 years--through World War II. Bismuth mining was replaced by large scale uranium mining from the late 1940 through 1989, employing some 400-450,000 workers, resulting in the major local epidemic of work-related cancer larger than anywhere in the world, so far amounting to ± 14-15,000 cases. Had the mine developers listened to the warnings by Agricola and Härting and Hesse, the epidemic could have been prevented.
Subject(s)
Lung Neoplasms/chemically induced , Mining/history , Occupational Diseases/chemically induced , Bismuth/toxicity , Germany , History, 15th Century , Humans , Lung Neoplasms/epidemiology , Miners , Occupational Diseases/epidemiology , Uranium/toxicityABSTRACT
Genotoxic effects of Bismuth (III) oxide nanoparticles (BONPs) were investigated on the root cells of Allium cepa by Allium and Comet assay. A. cepa roots were treated with the aqueous dispersions of BONPs at five different concentrations (12.5, 25, 50, 75, and 100ppm) for 4h. Exposure of BONPs significantly increased mitotic index (MI) except 12.5ppm, total chromosomal aberrations (CAs) in Allium test. While stickiness chromosome laggards, disturbed anaphase-telophase and anaphase bridges were observed in anaphase-telophase cells, pro-metaphase and c-metaphase in other cells. A significant increase in DNA damage was also observed at all concentrations of BONPs except 12.5ppm by Comet assay. The results were also analyzed statistically by using SPSS for Windows; Duncan's multiple range test was performed. These results indicate that BONPs exhibit genotoxic activity in A. cepa root meristematic cells.
Subject(s)
Bismuth/chemistry , Bismuth/toxicity , Comet Assay , Nanoparticles/toxicity , Onions/drug effects , Onions/genetics , Mutagens/chemistry , Mutagens/toxicity , Onions/cytology , Plant Roots/cytology , Plant Roots/drug effectsABSTRACT
Consumption and production of bismuth compounds are increasing, however, a little information on the toxic effect and also the effective method in removal of bismuth compounds are available. The present research aimed to characterize the potential efficiency of two chelators after bismuth administration for 55A days following two dose levels of 20 and 40A mg/kg body weight daily to male rats. However, we found abnormalities after bismuth administration in clinical signs, such as body weight, kidneys and liver damages, a black line on gums and skin reactions. Furthermore, the hypothesis that the two chelators might be more efficient as combined therapy than as single therapy in removing bismuth from the body was considered. Along this line, two known chelators deferiprone (1, 2-dimethy1-3-hydroxypyride-4-one, L(1)) and desferrioxamine (DFO) were chosen and tested in the acute rat model. Chelators were given orally (L(1)) or intraperitoneally (DFO) as a single or combined therapy for the period of a week. Doses of L(1) and DFO were 110A mg/kg body weight in experiments. Bismuth and iron concentrations in various tissues were determined by graphite furnace and flame atomic absorption spectrometry, respectively. The combined chelation therapy results show that DFO and L(1) are able to remove bismuth ions from the body, whereas iron concentration returned to the normal level and symptoms are also decreased. DFO was more effective than L1 in reducing bismuth concentration in tissues. The efficiency of DFOA +A L(1) is more than DFO or L(1) in removing bismuth from organs. Our results are indicative that the design procedure might be useful for preliminary in-vivo testing of the efficiency of chelating agents. Results of combined chelators' treatment should be confirmed in a different experimental model before extrapolation to other systems. This testing procedure of course does not provide all the relevant answers for efficiency of chelating agents in bismuth toxicity.
Subject(s)
Bismuth/metabolism , Deferoxamine/therapeutic use , Iron Chelating Agents/therapeutic use , Pyridones/therapeutic use , Siderophores/therapeutic use , Animals , Bismuth/pharmacokinetics , Bismuth/toxicity , Body Weight/drug effects , Chelation Therapy/methods , Deferiprone , Drug Therapy, Combination , Eating/drug effects , Iron/analysis , Iron/metabolism , Kidney/metabolism , Male , Rats , Rats, WistarABSTRACT
PURPOSE: The somatostatin analogue [DOTA0, Tyr3]octreotide (DOTATOC) has previously been labeled with low linear energy transfer (LET) beta-emitters, such as 177Lu or 90Y, for tumor therapy. In this study, DOTATOC labeled with the high-LET alpha-emitter, 213Bi, was evaluated. EXPERIMENTAL DESIGN: The radiolabeling, stability, biodistribution, toxicity, safety, and therapeutic efficacy of 213Bi-DOTATOC (specific activity 7.4 MBq/microg) were investigated. Biodistribution studies to determine somatostatin receptor specificity were done in Lewis rats at 1 and 3 hours postinjection. Histopathology of various organs was used to evaluated toxicity and safety. Therapeutic efficacy of 4 to 22 MBq 213Bi-DOTATOC was determined in a rat pancreatic carcinoma model. RESULTS: Radiolabeling of the 213Bi-DOTATOC was achieved with radiochemical purity >95% and an incorporation yield > or = 99.9%. Biodistribution data showed specific binding to somatostatin receptor-expressing tissues. Administration of free 213Bi, compared with 213Bi-DOTATOC, resulted in higher radioactivity accumulation at 3 hours postinjection in the kidneys [34.47 +/- 1.40% injected dose/g (ID/g) tissue versus 11.15 +/- 0.46%, P < 0.0001] and bone marrow (0.31 +/- 0.01% ID/g versus 0.06 +/- 0.02%, P < 0.0324). A significant decrease in tumor growth rate was observed in rats treated with >11 MBq of 213Bi-DOTATOC 10 days postinjection compared with controls (P < 0.025). Treatment with >20 MBq of 213Bi-DOTATOC showed significantly greater tumor reduction when compared with animals receiving <11 MBq (P < 0.02). CONCLUSIONS: 213Bi-DOTATOC showed dose-related antitumor effects with minimal treatment-related organ toxicity. No acute or chronic hematologic toxicities were observed. Mild, acute nephrotoxicity was observed without evidence of chronic toxicity. 213Bi-DOTATOC is a promising therapeutic radiopharmaceutical for further evaluation.
Subject(s)
Bismuth/toxicity , Bismuth/therapeutic use , Octreotide/analogs & derivatives , Octreotide/therapeutic use , Pancreatic Neoplasms/radiotherapy , Receptors, Somatostatin/drug effects , Animals , Disease Models, Animal , Drug Evaluation, Preclinical , Male , Octreotide/toxicity , Radioisotopes , Rats , Rats, Inbred Lew , Time FactorsABSTRACT
OBJECTIVE: To investigate whether acid suppression therapy influences the absorption of bismuth from colloidal bismuth pectin (CBP). METHODS: 48 male SD rats were randomly divided into five groups to be administer with different medicines once a day for 14 days: group A1 (administered with CBP only and killed on the cessation day of administration), group B1 (administered with CBP only and killed 8 weeks after the cessation of administration), group A2 [administered with CBP + amoxicillin (AMO) + metronidazole (MTR) + losec and killed on the cessation day of administration], group B2 (administered with CBP + AMO + MTR + losec and killed 8 weeks after the cessation of administration), and control group (administered with distilled water). The kidney issue sections were counterstained after AMG development. The bismuth deposited in tissues was observed by microscopy. The gray level of kidney tissue sections were measured and compared through image processing program. The deposition of bismuth and the degrees of cell organ's impairment were observed by electron microscopy. By using electron probe microanalysis bismuth was identified from the chemical elements in the specimens. RESULTS: Under the light microscopy, black-brown granules were discovered in the cell bodies of the proximal convoluted renal tubule. The amounts of bismuth accumulated in kidney of the 2 quadruple therapy groups were much more than those of the 2 single compound therapy groups (all P < 0.05). The amount of bismuth accumulated in kidney on the cessation day of administration was more than that eight weeks later (both P < 0.01). Under electron microscopy, black-brown granules were observed exclusively in the lysosomes of the proximal convoluted renal tubule cell. Electron microscopy found cell impairment in the quadruple therapy groups. Impairment of these cells could be recovered 8 weeks after the cessation of administration. CONCLUSION: Acid suppression therapy causes an increase of absorption and accumulation of bismuth from CBP in the kidney. Bismuth can be accumulated in the cell bodies of proximal convoluted renal tubule after its absorption. The absorbed bismuth can be discharged out of the body via kidney. Large amounts of bismuth accumulation in kidney can impair the functions of proximal convoluted renal tubule cells.
Subject(s)
Antacids/adverse effects , Bismuth/pharmacokinetics , Helicobacter Infections/drug therapy , Helicobacter pylori , Kidney/metabolism , Amoxicillin/pharmacokinetics , Animals , Bismuth/administration & dosage , Bismuth/toxicity , Colloids/administration & dosage , Colloids/pharmacokinetics , Drug Therapy, Combination , Kidney/pathology , Male , Metronidazole/pharmacokinetics , Pectins/administration & dosage , Pectins/pharmacokinetics , Random Allocation , Rats , Rats, Sprague-DawleyABSTRACT
We used a pretargeting technique to treat a nonobese diabetic/severe combined immunodeficient murine model of human adult T-cell leukemia with an anti-Tac antibody-streptavidin (HAT-SA) conjugate, which recognizes CD25, followed by bismuth 213 ((213)Bi)-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)- biotin. In the 3-step pretargeting radioimmunotherapy protocol, HAT-SA (140 or 400 microg) was administered intravenously (i.v.) to bind to the interleukin 2 receptor alpha (IL-2R alpha; CD25)-expressing tumor cells. After 24 hours, 100 microg of a synthetic clearing agent was administered i.v. to remove unbound circulating HAT-SA conjugate from the circulation. Four hours later, (213)Bi-DOTA-biotin was administered i.v. for therapy. Tumor growth was significantly inhibited in 3 trials by using 250 microCi (9.25 MBq) of (213)Bi-DOTA-biotin with a pretargeting technique as monitored by serum levels of soluble IL-2R alpha and/or human beta-2-microglobulin (P <.05, t test) and by survival of tumor-bearing mice in the treatment groups (P <.02, log rank test) as compared with the control groups. No prolongation of survival was observed with a nonspecific antibody-SA conjugate or in the absence of the radionuclide. Additionally, no prolongation of survival resulted from administration of (213)Bi directly linked to intact HAT. Furthermore, there was no prolongation of survival when the beta-emitting radionuclide yttrium 90 instead of the alpha-emitting radionuclide (213)Bi was used. The pretargeting approach with (213)Bi inhibited tumor growth more effectively than did immunotherapy with unmodified HAT. The best results were obtained with combination therapy that involved (213)Bi-DOTA-biotin with a pretargeting technique supplemented by 4 weekly doses of HAT. The findings of this study support the use of this combination approach in a clinical trial in patients with IL-2R alpha-expressing leukemias.
Subject(s)
Bismuth , Leukemia-Lymphoma, Adult T-Cell/radiotherapy , Radioimmunotherapy/methods , Radioisotopes , Alpha Particles , Animals , Antigens, Neoplasm/immunology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/toxicity , Biotin , Bismuth/administration & dosage , Bismuth/pharmacokinetics , Bismuth/toxicity , Heterocyclic Compounds, 1-Ring , Mice , Mice, Inbred NOD , Neoplasms, Experimental/therapy , Radioisotopes/administration & dosage , Radioisotopes/pharmacokinetics , Radioisotopes/toxicity , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/pharmacokinetics , Radiopharmaceuticals/toxicity , Receptors, Interleukin-2/immunology , Streptavidin , Survival Rate , Treatment OutcomeABSTRACT
We provide a detailed protocol of the autometallographic bismuth technique and evaluate the specificity of the technique. We show by the multi-element technique "proton-induced X-ray microanalysis" (PIXE) that the autometallographic grains contain silver, bismuth, and sulfur, proving that autometallography can be used for specific tracing of bismuth bound as bismuth sulfide clusters in tissue sections from Bi-exposed animals or humans. In sections from animals exposed concurrently to selenium and bismuth, the autometallographic grains also contain selenium. This demonstrates that, if present in excess in the organisms, selenium will bind to exogenous bismuth, creating bismuth selenide clusters. As a further possible control for specificity and as a tool for differentiating among autometallographically detectable metals in sections containing more than one, we describe how bismuth sulfide clusters can be removed from Epon-embedded tissue sections by potassium cyanide.
Subject(s)
Bismuth/metabolism , Animals , Bismuth/chemistry , Bismuth/toxicity , In Vitro Techniques , Indicators and Reagents , Mice , Mice, Inbred BALB C , Organ Specificity , Potassium Cyanide , Rats , Rats, Wistar , Selenium/chemistry , Selenium/metabolism , Selenium/toxicity , Silver Staining/methods , Spectrometry, X-Ray Emission , Sulfides/chemistryABSTRACT
Although bismuth poisoning is still a rare phenomenon, the increasing use of bismuth-containing drugs warrants a systematic approach to the treatment of bismuth overdose. An effective method of enhancing the elimination of toxic amounts of bismuth from the body has not been reported. Therefore we performed a study to select the best chelator to treat bismuth poisoning. Dimercaprol (BAL), meso-2,3-dimercaptosuccinic acid (DMSA), D,L-2,3-dimercapto-propane-I-sulfonic acid (DMPS), D-penicillamine (D-PEN), N-acetyl-D,L-penicillamine (Ac-PEN), thiopronine (TP), sodium-calcium edetate (EDTA) and deferoxamine (DFO) were tested with an in vitro model of equilibrium dialysis and an in vivo model of rats poisoned with bismuth. The rats (n = 6 per substance tested) were treated with the chelators in intraperitoneal doses of 250 mumol/kg.day for 3 consecutive days. Afterward, tissue and blood samples were collected. Bismuth concentrations were determined with electrothermal atomic absorption spectrometry in serum, buffer, urine, blood, brain, kidney, liver, spleen, and bone. Using in vitro results, we constructed a ranking of chelating agents; it appeared not to predict the in vivo results. The dithiol compounds (DMPS, DMSA and BAL) were effective in most organs (especially in kidney and liver) resulting in a higher elimination of bismuth in urine by DMPS and BAL. BAL was the only chelator effective in lowering brain bismuth concentrations, whereas treatment with EDTA resulted in increased brain bismuth levels. For D-PEN and DFO, no effects could be demonstrated. For clinical practice, DMSA and DMPS may well be the chelators of choice; the application of BAL should be reserved for very severe cases of poisoning because of its own toxicity.
Subject(s)
Bismuth/toxicity , Chelating Agents/therapeutic use , Animals , Biological Transport , Bismuth/metabolism , Female , Protein Binding , Rats , Rats, Inbred Strains , Time Factors , Tissue DistributionABSTRACT
In a cross-over study in ten healthy volunteers the effect of food on the absorption of bismuth following a single oral dose of 1200 mg (= 12 Bismofalk tablets) was evaluated by measuring its serum levels (0 to 24 h) and urinary excretion (for seven days). If this high dose was ingested one hour prior to the breakfast maximal serum concentrations (16.5 +/- 13.7 micrograms/l; mean +/- SD) were rapidly achieved (tmax = 0.7 +/- 0.5 h). These levels and the low urinary recovery of 0.32 +/- 0.25 mg (corresponding to 0.027% of the dose) indicated a minimal absorption. If the tablets were taken one hour after the breakfast absorption was slightly delayed (tmax = 1.9 +/- 2.4 h), however, the extent appeared to be unchanged. In spite of the high dosage as well as the large interindividual variability in the urinary recovery and the serum concentrations potential "toxic" serum levels of 100 micrograms/l were never reached. Thus, it can be concluded that the bismuth preparation used is suitable for topical action.
Subject(s)
Antacids , Anti-Infective Agents , Bismuth/administration & dosage , Bismuth/pharmacokinetics , Eating/physiology , Gallic Acid/analogs & derivatives , Intestinal Absorption/physiology , Organometallic Compounds/administration & dosage , Administration, Oral , Adult , Bismuth/toxicity , Dose-Response Relationship, Drug , Drug Combinations , Female , Gallic Acid/administration & dosage , Gallic Acid/toxicity , Humans , Male , Organometallic Compounds/toxicity , Reference ValuesSubject(s)
Contrast Media , Dentures , Methylmethacrylates , Animals , Bismuth/toxicity , Carbonates , Chemical Phenomena , Chemistry, Physical , Contrast Media/toxicity , Drug Combinations , Drug Evaluation, Preclinical , Fishes , Mandible/surgery , Methylmethacrylate , Methylmethacrylates/toxicity , RatsABSTRACT
Examination of twelve cases of bismuth encephalopathy showed a constantand marked elevation of the bismuth levels in autopsy cerebral tissue (ranging from 2-8 mg/kg to 25 mg/kg). These values were found to be much higher than the last-measured Bismuth venous blood values. In every case, periveinular lymphocytic infiltration and abundant intra-cytoplasmic lipofuscin were seen. The microanalysis with Castaing's electrode revealed the presence of focal areas of bismuth in the leptomeningeal spaces. The significance of the lesions is not fully established and it will undergo further investigations.
Subject(s)
Bismuth/toxicity , Brain Diseases/chemically induced , Adult , Aged , Bismuth/analysis , Bismuth/blood , Brain Diseases/pathology , Cerebellar Cortex/analysis , Cerebral Cortex/analysis , Cerebral Cortex/pathology , Female , Humans , Kidney/pathology , Lipofuscin/analysis , Male , Middle Aged , Thalamus/analysisABSTRACT
Tri-potassium di-citrato bismuthate is a complex bismuth salt stable in colloidal form advocated for the treatment of peptic ulcer. Preliminary placebo-controlled trials in small numbers of ambulant patients with endoscopically proven peptic ulcer, strongly suggest that the compound accelerates the rate of healing of gastric and duodenal ulcer within 4 weeks of treatment. However, trials involving larger numbers of patients followed-up for longer periods are required before a clear verdict on the efficacy of tripotassium di-citrato bismuthate in gastric and duodenal ulcer can be given. There are no reliable data on the effect of the drug on ulcer recurrence rate. Side-effects are negligible and the drug could become an important therapeutic agent in peptic ulcer therapy if results of further study are conclusive. The drug causes dark discolouration of the stools and this should be borne in mind when considering the possibility of the presence of intestinal bleeding.